HealthMore in Health→
Eli Lilly Says Verve Gene-Editing Therapy Cut Cholesterol in Early Trial
Key Takeaways
- Lilly says a high dose of VERVE-102 reduced cholesterol by 62% in an early study.
- The result points to early biological activity for a gene-editing therapy.
- Key questions on safety, durability, and larger-trial performance remain open.
DE
DT Editorial Team··via statnews.com
